--- title: "股東行動警報：Schall 律師事務所鼓勵 Akero Therapeutics, Inc.的投資者與該公司聯繫，以處理損失" description: "Schall 律師事務所已經為 Akero Therapeutics, Inc.的投資者發佈了股東訴訟警報。這起集體訴訟指控公司違反證券法，併發布了誤導性聲明。鼓勵遭受損失的投資者在 2024 年 6 月 25 日之前與該律師事務所聯繫，以參與此案" type: "news" locale: "zh-HK" url: "https://longbridge.com/zh-HK/news/203023313.md" published_at: "2024-04-29T00:21:13.000Z" --- # 股東行動警報：Schall 律師事務所鼓勵 Akero Therapeutics, Inc.的投資者與該公司聯繫，以處理損失 > Schall 律師事務所已經為 Akero Therapeutics, Inc.的投資者發佈了股東訴訟警報。這起集體訴訟指控公司違反證券法，併發布了誤導性聲明。鼓勵遭受損失的投資者在 2024 年 6 月 25 日之前與該律師事務所聯繫，以參與此案 LOS ANGELES, April 28, 2024 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Akero Therapeutics, Inc. (“Akero” or “the Company”) (NASDAQ: AKRO) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company’s securities between September 13, 2022 and October 9, 2023, inclusive (the “Class Period”), are encouraged to contact the firm before June 25, 2024. If you are a shareholder who suffered a loss, click here to participate. We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at bschall@schallfirm.com. The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member. According to the Complaint, the Company made false and misleading statements to the market. 20% of the patients enrolled in Akero’s SYMMETRY study suffered from cryptogenic cirrhosis and did not have definitive NASH at baseline. These patients did not have biopsy-proven compensated cirrhosis. The SYMMETRY study excluded these patients when calculating the NASH resolution secondary endpoints. The Company influenced the study’s results and increased its likelihood of failing to reach its primary endpoint by introducing confounding factors to the study. The SYMMETRY study failed to align with FDA guidance by not ruling out potential causes for each patients’ cirrhosis. Based on these facts, the Company’s public statements were false and materially misleading throughout the class period. When the market learned the truth about Akero, investors suffered damages. Join the case to recover your losses. The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics. **CONTACT:** The Schall Law Firm Brian Schall, Esq., www.schallfirm.com Office: 310-301-3335 info@schallfirm.com **SOURCE:** The Schall Law Firm ### Related Stocks - [AKRO.US - Akero Therapeutics](https://longbridge.com/zh-HK/quote/AKRO.US.md) ## Related News & Research | Title | Description | URL | |-------|-------------|-----| | 21:59 ETACROBiosystems fördert Innovationen bei JPM Spotlight-Sessions von bioSeedin und unterstützt strategisch den Aufbau globaler Partnerschaften | ACROBiosystems participated in the BIOSeedin Winter Innovation Partnering Summit on January 11, ahead of J.P. Morgan 202 | [Link](https://longbridge.com/zh-HK/news/275692064.md) | | Officer Rolph Acquires 152,678 Of Akero Therapeutics Inc [AKRO] | Officer Rolph Timothy of Akero Therapeutics Inc filed a Form 4 with the SEC, disclosing the acquisition of 152,678 share | [Link](https://longbridge.com/zh-HK/news/267848573.md) | | Rakovina Therapeutics Appoints Kim Oishi as CEO and Director | Rakovina Therapeutics Inc. has appointed Kim Oishi as CEO and Director. Dennis Brown has resigned from the Board of Dire | [Link](https://longbridge.com/zh-HK/news/273889407.md) | | Akero Therapeutics Presents New Analyses from Phase 2b SYMMETRY and HARMONY Trials of Efruxifermin at 76th Annual AASLD The Liver Meeting® 2025 | Post-hoc analyses corroborate previously reported antifibrotic effects of efruxifermin observed in 96-week Phase 2b SYMM | [Link](https://longbridge.com/zh-HK/news/264878201.md) | | CEO Cheng Gifts 74,538 Of Akero Therapeutics Inc [AKRO] | Cheng Andrew Chief Executive Officer of Akero Therapeutics Inc [AKRO] filed a Form 4 on November 21, 2025 with the Secur | [Link](https://longbridge.com/zh-HK/news/266990863.md) | --- > **免責聲明**：本文內容僅供參考，不構成任何投資建議。